Hepatitis B Virus Core Antigen (HBcAg) Antikörper (Cy3)

Produktnummer ABIN722994

Produktdetails

Target: Hepatitis B Virus Core Antigen (HBcAg)

Reaktivität: Hepatitis B Virus (HBV), Virus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Cy3

Applikation: Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Kreuzreaktivität: Virus

Kreuzreaktivität (Details): Hepatitis B Virus

Aufreinigung: Purified by Protein G.

Immunogen: Recombinant Hepatitis B Core Antigen (rHBcAg)

Klon: 1H8

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: Hepatitis B Virus Core Antigen (HBcAg)

Andere Bezeichnung: HBcAg (HBcAg Produkte)

Synonyme: precore; HBe antigen; PreC; HBeAg; precore protein; external core antigen; HBeAg; p25 antikoerper, C antikoerper

Substanzklasse: Viral Protein

Hintergrund:

Synonyms: C, Capsid protein, Core and e antigen, Core antigen, Core antigen, Core protein, HBc, HBcAg, HBVgp4, Hepatitis B Virus core antigen, p21.5, precore/core protein, CAPSD_HBVA3.

Background: Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection.The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection.